Abstracts tagged "interstitial lung disease"

Abstract Number: 1647 • ACR Convergence 2022
Increased Risk of Lung Cancer in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Matched Cohort Study with Cancer Registry Linkage
Rebecca Brooks¹, Yangyuna Yang¹, Punyasha Roul², Brent Luedders¹, Namrata Singh³, Brian Sauer⁴, Grant Cannon⁵, Joshua Baker⁶, Ted Mikuls⁷ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC, Omaha, NE, ³University of Washington, Bellevue, WA, ⁴Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁵Retired, Salt Lake City, UT, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: While patients with RA are predisposed to developing lung cancer, prior epidemiologic studies have been limited in their ability to account for potential confounders…
Abstract Number: 2248 • ACR Convergence 2022
Prevalence and Mortality of Interstitial Lung Abnormalities in Rheumatoid Arthritis and non-RA Comparators in a Multicenter Prospective Cohort
Gregory McDermott¹, Keigo Hayashi², Kazuki Yoshida¹, Matthew Moll¹, Michael Cho¹, Tracy Doyle¹, Paul Dellaripa¹, Rachel Putman¹, Raul San Jose Estepar¹, George Washko¹, Elizabeth Regan³, Hiroto Hatabu¹, Gary M Hunninghake¹, Edwin Silverman¹ and Jeffrey Sparks⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ³National Jewish Health, Denver, CO, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Subpleural interstitial lung abnormalities (ILA) may be a form of subclinical or preclinical interstitial lung disease (ILD) and have been reported in up to…
Abstract Number: 0191 • ACR Convergence 2022
Patient-reported Outcomes to Assess Dyspnea in Connective Tissue Diseases, Interstitial Lung Disease and Pulmonary Hypertension, a Systematic Literature Review of Measurement Properties
Jacqueline Lemmers¹, Madelon Vonk² and Els Ende, van den³, ¹Radboud University Medical Centre Nijmegen, Nijmegen, Netherlands, ²Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ³Radboudumc, Nijmegen, Netherlands
Background/Purpose: This COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN)-based systematic review aims to identify and summarize the quality of measurement properties of…
Abstract Number: 0910 • ACR Convergence 2022
Rheumatoid Arthritis Associated Interstitial Lung Disease: The Role of Non-Criteria Autoantibodies
Albert Pérez-Isidro¹, Raul Castellanos-Moreira¹, Juan Camilo Sarmiento-Monroy², Noemi de Moner¹, Maresa Grundhuber³, Odette Vinas¹, Raimon Sanmarti² and Estibaliz Ruiz-Ortiz¹, ¹Hospital Clinic of Barcelona, Barcelona, Spain, ²Hospital Clínic de Barcelona, Barcelona, Spain, ³Thermo Fisher Scientific, Freiburg, Germany
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic joint inflammation. RA-associated interstitial lung disease (ILD) is the most frequent and severe extra-articular…
Abstract Number: 1214 • ACR Convergence 2022
In-hospital Outcomes of Autoimmune Diseases Complicated by Interstitial Lung Disease: A National Inpatient Sample Analysis
Sandhya shri Kannayiram¹ and Shilpa Arora², ¹John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, ²Rush University Medical Center, Chicago, IL
Background/Purpose: Several autoimmune diseases (AD) may be associated with interstitial lung disease (ILD), contributing to increased morbidity and mortality in these patients. We aimed to…
Abstract Number: 1659 • ACR Convergence 2022
FAM13A (Family with Sequence Similarity 13 Member A) Polymorphism Is Associated with Presence of a Radiographic Usual Interstitial Pneumonia Pattern in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
Elana Bernstein¹, Francesco Boin², Brett Elicker³, Yawen Ren⁴, John Varga⁵ and Shervin Assassi⁶, ¹Columbia University, New York, NY, ²Cedars-Sinai Medical Center, Los Angeles, CA, ³University of California San Francisco, San Francisco, CA, ⁴University of Texas Health Science Center at Houston, Houston, TX, ⁵University of Michigan, Ann Arbor, MI, ⁶McGovern Medical School, University of Texas, Houston, TX
Background/Purpose: The pathogenesis of SSc-associated interstitial lung disease (ILD) is incompletely understood. The MUC5B promoter gain-of-function single nucleotide polymorphism (SNP) rs35705950 has been associated with…
Abstract Number: 2249 • ACR Convergence 2022
Impact of Interstitial Lung Disease on COVID-19 Severity Among Patients with Rheumatoid Arthritis: A Multicenter Comparative Study
Gabriel Figueroa Parra¹, Emily Gilbert², Maria Valenzuela Almada¹, Sebastian Vallejo¹, Matthew Neville³, Naomi Patel⁴, Claire Cook⁵, Xiaoqing Fu⁵, Ramla Hagi⁵, Gregory McDermott⁶, Michael Dilorio⁶, Lucy Masto⁶, Kathleen Vanni⁶, Emily Kowalski⁶, Grace Qian⁶, Zachary Wallace⁵, Ali Duarte-Garcia¹ and Jeffrey Sparks⁷, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Jacksonville, FL, ³Mayo Clinic, Phoenix, AZ, ⁴Massachusetts General Hospital, Sale Creek, TN, ⁵Massachusetts General Hospital, Boston, MA, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) has been associated with severe COVID-19, but few studies have investigated outcomes in RA phenotypes such as interstitial lung disease (RA-ILD),…
Abstract Number: 0245 • ACR Convergence 2022
Influence of Forced Vital Capacity Impairment on Treatment Selection and Outcomes in RA-ILD Patients Initiating a Biologic or Targeted-Synthetic DMARD
Bryant England¹, Michael George², Yangyuna Yang¹, Punyasha Roul³, Jorge Rojas⁴, Brian Sauer⁵, Grant Cannon⁶, Joshua Baker⁷, Jeffrey Curtis⁸ and Ted Mikuls⁹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³UNMC, Omaha, NE, ⁴George E. Wahlen Department of Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶Salt Lake City VA, Salt Lake city, ⁷University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, ⁸Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁹Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Patients with RA-associated interstitial lung disease (RA-ILD) suffer from substantial morbidity and premature mortality. The optimal use of biologic/tsDMARDs in this population is poorly…
Abstract Number: 0920 • ACR Convergence 2022
Retention Rate and Safety of Biologic or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs (DMARDs) in Patients with Rheumatoid Arthritis Associated with Interstitial Lung Disease: Results from the KOBIO Registry
Ji-Won Kim¹, Sun-Kyung Lee², Ju-Yang Jung¹, Chang-Hee Suh³, Kichul Shin⁴ and Hyoun-Ah Kim¹, ¹Ajou University School of Medicine, Suwon, Republic of Korea, ²Hanyang university, Seoul, Republic of Korea, ³Ajou University Hospital, Suwon, Republic of Korea, ⁴Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, Republic of Korea
Background/Purpose: The aim was to evaluate long-term drug retention and safety of biologic (bDMARDs) or targeted synthetic disease modifying anti-rheumatic drugs (tsDMARDs) and to identify…
Abstract Number: 1231 • ACR Convergence 2022
[68Ga]- CPCR4 Trifluoroacetate PET/CT Imaging of Chemokine Receptor CXCR4- Expression in Systemic Sclerosis Related Interstitial Lung Disease
Chirag Rajkumar Kopp¹, Shefali Sharma², Venkata Subramanian Krishnaraju³, Chandra Bhushan Prasad³, Jagdeep Singh³, Shashi Anand³, Ranjana Minz³, Ashwani Sood³, Anindita Sinha³, Rajender Kumar Basher³, Sahajal Dhooria³, Varun Dhir⁴ and sanjay jain³, ¹Post Graduate Institute of Medical Education and Research, Chandigarh, India, ²PGIMER< Chandigarh, Chandigarh, India, ³Postgraduate Institute of Medical Education and Research, Chandigarh, India, ⁴PGIMER, CHD, INDIA, Chandigarh, India
Background/Purpose: Interstitial lung disease (ILD) in Systemic sclerosis (SSc) is a major contributor of morbidity and mortality. CXCR4/CXCL12 axis has been implicated in the pathogenesis…
Abstract Number: 1855 • ACR Convergence 2022
Clinical Outcomes in an Observational Retrospective Cohort of Patients with Connective Tissue Disease-associated Interstitial Lung Disease (CTD-ILD) Who Taper Immunosuppressive Therapy
Paul Dellaripa, Paul Hoover and Tracy Doyle, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Patients with CTD-ILD are often treated with a combination of corticosteroids and steroid sparing agents to limit the progression of the inflammatory response in…
Abstract Number: 2250 • ACR Convergence 2022
Genetic and Environmental Risk Factors in Rheumatoid Arthritis-Associated Interstitial Lung Disease
Austin Wheeler¹, Yangyuna Yang¹, Joshua Baker², Jill Poole¹, Dana Ascherman³, Gail Kerr⁴, Andreas Reimold⁵, Gary Kunkel⁶, Grant Cannon⁷, Katherine Wysham⁸, Namrata Singh⁹, Deana Lazaro¹⁰, Paul Monach¹¹, S. Louis Bridges, Jr.¹², Ted Mikuls¹³ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³University of Pittsburgh, Pittsburgh, PA, ⁴Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁵University of Texas Southwestern Medical Center, Dallas, TX, ⁶University of Utah, Salt Lake City, UT, ⁷Retired, Salt Lake City, UT, ⁸VA Puget Sound/University of Washington, Seattle, WA, ⁹University of Washington, Bellevue, WA, ¹⁰VA New York Harbor Healthcare system, Short Hills, NJ, ¹¹VA Boston Healthcare System, Boston, MA, ¹²Hospital for Special Surgery, New York, NY, ¹³Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: RA-associated interstitial lung disease (RA-ILD) is an extra-articular manifestation of RA causing substantial morbidity and mortality. Genetic risk variants, such as the MUC5B rs35705950…
Abstract Number: 0248 • ACR Convergence 2022
Monocyte Chemoattractant Protein-1, Vascular Cell Adhesion Protein-1 and Asymmetric Dimethylarginine as Potential Biomarkers of Interstitial Lung Disease Associated with RA
Veronica Pulito-Cueto¹, Sara Remuzgo-Martinez¹, Fernanda Genre¹, Belén Atienza-Mateo¹, Víctor M. Mora-Cuesta¹, David Iturbe-Fernández¹, Leticia Lera-Gómez¹, Diana Prieto-Peña¹, Virgi Portilla¹, Ricardo Blanco², Alfonso Corrales¹, Oreste Gualillo³, José M. Cifrián¹, Raquel Lopez Mejias⁴ and Miguel Ángel González-Gay⁵, ¹Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Hospital Clínico Universitario de Santiago, SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), NEIRID Lab (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Research Laboratory 9, Santiago de Compostela, Spain, ⁴IDIVAL, Santander, Spain, ⁵Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Interstitial lung disease (ILD) is one of the main comorbidities of patients with RA contributing to an increased mortality risk [1]. The pathogenesis of…
Abstract Number: 1047 • ACR Convergence 2022
A Novel Prediction Tool for Progression of Systemic Sclerosis-Interstitial Lung Disease Despite Treatment with Immunosuppression
Elizabeth Volkmann¹, Holly Wilhalme¹, Grace Kim¹, Jonathan Goldin¹, Shervin Assassi², Masataka Kuwana³, Donald Tashkin¹ and Michael roth¹, ¹University of California Los Angeles, Los Angeles, CA, ²McGovern Medical School, University of Texas, Houston, TX, ³Nippon Medical School Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Systemic sclerosis-interstitial lung disease (SSc-ILD) is the leading cause of SSc-related death. While some patients respond favorably to treatment with immunosuppression, a subset of…
Abstract Number: 1246 • ACR Convergence 2022
Improving Radiologic Interpretation of Diffuse Lung Disease in Pediatric Rheumatologic (PR) Patients Using Trained Scoring with Semi-quantitative Chest Computed Tomography (CT) Analysis
Michal Cidon¹, Beverley Newman², Terry Robinson³, Paul Iskander⁴, Paul Thacker⁵, Evan Zucker², Tzielan Lee⁶ and Rex Moats³, ¹Children's Hospital Los Angeles, Los Angeles, CA, ²Stanford Children's Health, Stanford, CA, ³Children's Hospital of Los Angeles, Los Angeles, CA, ⁴University of California Los Angeles, Los Angeles, CA, ⁵Mayo Clinic, Rochester, MN, ⁶Stanford University School of Medicine, Palo Alto, CA
Background/Purpose: We presented preliminary data in 2021 to support the feasibility of using a semi-quantitative chest CT scoring system (Pediatric Rheumatologic Diffuse Lung Disease Score…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].